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Pakistan is one of the countries with the highest number of medications filled per prescription due to overly prescribed antibiotics and 
injectable drugs. This is due to a lack of ethical practices in prescribing because doctors are significantly influenced by lucrative financial 
incentives of pharmaceutical companies rather than clinical findings. This immoral activity has become significantly amplified over the 
past few years and continues to be a challenge in Pakistan. Currently, there is no code of ethics for marketing and promotional activities 
of pharmaceutical companies. This year, authorities have step up and are in the process of creating policies to regulate companies and 
practitioners. Implementation of these new policies needs vigilance from health officials, strong professional commitment and 
institutional collaboration. If executed correctly, these polices should create an environment of professionalism within the healthcare 
sector. 
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Introduction 
According to the World Health Organization (WHO), Pakistan is 
the fifth most populous developing country in the Eastern 
Mediterranean Region.1 Pakistan has a significant deficiency in 
the health budget and lacks efficiency  with regards to 
regulation of the health sector.2 A sizable proportion of the 
health care system is made up of private firms.3 According to 
the Human Development Index (HDI), Pakistan is ranked 145 
amongst 189 countries with regards to life expectancy and  
has a lower life expectancy than Indonesia, Malaysia, and Sri 
Lanka.1 In Pakistan, 77% of healthcare expenditures revolve 
around medication purchase.4 Inappropriate medication use is 
a significant concern with antibiotics, anti-cancer, hormones, 
narcotics; and psychotropic being misused the most often.5 
 
 In Pakistan, the average number of drugs per prescription  
was 4.4, which is highest in the world.6 Overprescribing of 
antibiotics was documented, however about 70% patients were 
prescribed antibiotics 5,6. Large number of prescriptions were 
found inappropriate in Pakistan specifically antimicrobials 
about 60% patients prescribed antimicrobials and less 20% 
patients were prescribed properly7 Large number of qualified 
medical practitioners frequently prescribe inappropriately 
even for prevalent diseases  like treatment for psychiatric and 
pediatrics diseases did not relate to diagnosis in 25% cases and 
doses of medicines were incorrect in 31% prescriptions. More 
than 76.5% medicines of the unknown composition which 
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mixtures made in their own medicine dispensing area which is 
not open to monitoring.5 Globally, Pakistan has the highest rate 
of injectable medication use, with more than 60 percent of 
patients receiving prescriptions—it is estimated that 90% of 
these prescriptions were unneccessary.4 In addition to the 
overprescribing of unnecessary medications, many prescribers 
also add new, expensive, first- line therapies along with 
concomitant use of over-the-counter products such as 
multivitamins and minerals which leads to poly-pharmacy 
complications.8   To make matters worse,   more than  50% of  
medications  are prescribed for the brand name which further 
impacts the economic burden placed on patients.6  
 
In developing countries like Pakistan, the largest contributing 
factors to irrational use of medications are unethical practices 
from prescribers, pharmaceutical companies, and regulatory 
authorities.9 Prescription analysis is essential in identifying the 
root cause of poor prescribing habits and creating long-term 
solutions. The WHO has suggested five basic indicators that can 
help flag irrational prescribing habits. These indicators are: the 
number of medications prescribed, trends associated with 
overprescribed medications such as antibiotics and injections, 
the percentage of generic vs.  brand name prescriptions, 
dispensing and consulting time and the number of drugs from 
the National Essential Medicine List (NEML).10 Rational 
prescribing and quality use of medications remains a neglected 
domain within medical practice in Pakistan.14 The International 
Network for the Rational Use of Drugs (INRUD) and WHO Action 
Program on Essential Drugs (WHO/DAP) collaborate and 
support many developing countries like Zimbabwe  
and Indonesia. They provide international indicators, 
methodologies and standard to deliver benchmark. Since the 
assistance of these programs, the ethical prescribing of 
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Medicine marketing and irrational prescriptions 
Globally, the annual corruption expenditure is estimated to be 
$4.4 trillion dollars with the majority of these unethical 
practices occurring in the healthcare sector.16 Bribery impacts 
not only developing countries such as India and Pakistan, but 
also established markets such as  China,  United Kingdom and  
The United States.17 The goal would be to target deceitful 
practices in the pharmaceutical sector and address issues such 
as bribery, embezzlement, falsification of safety information, 
forgery of efficacy, preferential contracts with  companies and 
burglary within the supply chain.16 The Department of Justice in 
the US has already fined pharmaceutical companies billions of 
dollars for unethical marketing. The pharmaceutical companies 
in  United Kingdom has lost between 10% and 25% due to  
health care  corruption and even China has experienced 
significant problems due to the same unethical practices.17  
 
Currently, Pakistan has more than 600 medication 
manufacturing units and 88,000 registered medicinal products 
which is the highest number of drug products among 
underdeveloped countries.1,5 Due to the large number of 
pharmaceutical companies, the competition is fierce and many 
businesses commence unethical promotional tools and 
activities to attain a market share.15 The associations between 
physicians and companies has become more business 
oriented19  and this significantly influences the prescribing 
behavior.  Prescribers are swayed to dispense certain products 
by receiving gifts that include: books, cars, clinical appliances, 
membership to associations, drug samples, fancy dinners, 
home appliances, seminars, and funding for conferences.17,20  
To gain maximum financial benefit from pharmaceutical 
companies, doctors prescribe the maximum number of drug 
products, which22 increases the cost of medical care for 
patients. More than 60% of pharmaceutical companies confess 
that contemporary marketing activities are unethical and 51% 
admit guilt for these practices.23 Strong healthcare legislation 
must be introduced to control and reverse these immoral 
practices.24  
 
Prescribing medications by brand names 
In Pakistan, most prescribers write for brand name 
prescriptions8,16 which has led to a substantial increase in costs 
for patients.26,27 It is important to enact appropriate legislations 
and policies to prohibit these practices.  
 
Frame of policies and efforts in Pakistan  
In 2004, WHO strategized a program entitled “Good 
Governance for Medicine” (GGM), its initiative to concretely 
address the need for transparency and unethical marketing of 
medication in various parts of world. Moreover, to stimulate 
individual and influential reliability in the pharmaceutical 
sector. This program operates in more than 26 countries 
globally and includes Malaysia, People’s Democratic Republic 
Lao, Philippines and Thailand.28 Guidelines such as transparency 
in revision of pharmaceutical laws and regulations to meet 
international recognized standard,  transparent medicine 
procurement which leads towards fairer competition  gained 
from this program can be helpful for prospective efforts and 
strategies in Pakistan.15 GGM recommends that policy changes 
alone is not adequate to overcome the corruption, there must 
be a strong level of commitment coupled with the collaboration 
of anti-corruption agencies to bring about change.28  
 
As of now, certain provincial authorities have made a small 
number of  policies to ensure prescribers are following ethical 
prescribing habits and ensuring generic forms of the medication 
are being dispensed; however, this number is far too few to 
have a significant impact on the greater population.31,32,33  
 
In the past, the Pakistan Medical & Dental Council (PMDC) 
established a code of ethics for practitioners (1962) and its final 
revised form was introduced in 2001. These codes of ethics 
drew attention to the importance of rational drug use and 
clearly notates that practitioners should not accept any 
financial kickbacks.9 However, this sector seems to be ignored 
by health authorities as well as policymakers. 
 
In September 2016, the Drug Regulatory Authority of Pakistan 
(DRAP) stepped forward to draft a code of conduct for 
pharmaceutical companies in an attempt to monitor drug 
promotion activities. A committee of experts has been 
appointed to outline the policy and will consist of healthcare 
providers, governmental officials, and representatives of the 
consumer councils. The ultimate goal will be to ensure ethical 
prescribing habits by monitoring the ties between companies 
and healthcare practitioners.29,30 Authorities are planning to 
pilot this project in government hospital immediately and 
expand to33 all the provincial areas. 
 
Conclusion 
Hopefully, the creation of new policies will help to overcome 
the unethical marketing of pharmaceutical companies and will 
change the current prescribing behavior of healthcare 
providers. If the policies are enforced appropriately, we should 
see prescribers writing prescriptions for clinical efficacy with 
patient affordability in mind. We should see an increase in the 
prescribing of drugs by their generic name which will help to 
safeguard the rights of patients and their interest. Additionally, 
promotional budgets for medication marketing will be 
controlled and should help to minimize the medication prices 
and increase the availability of cost-effective medicines. In 
short, these policies will ultimately decrease the economic 
burden on patients and increase the accessibility to quality 
medicine. Furthermore, it should also increase the 
professionalism in practitioners and pharmaceutical 
companies. In short, these policies should be potential 
landmarks in the healthcare system of Pakistan. It is important 
to note that implementation of these polices will take time, but 
proper execution will ensure success. Through the use of 
vigilance, dedication, professional commitment and 
institutional collaboration, we can bring the necessary change 
to improve the healthcare landscape in Pakistan. 
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